Results 51 to 60 of about 18,733 (258)

Body - Mind Medicine and the Placebo Response

South African Family Practice, 1992
No abstract available.
B. Brom
doaj   +1 more source

Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects

Scientific Reports, 2022
Placebos are known to yield significant effects in many conditions. We examined deceptive and open-label placebo effects on guilt, which is important for self-regulation and a symptom of mental disorders.
Dilan Sezer, Cosima Locher, Jens Gaab
doaj   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Clinical efficacy of probiotic mouthwash in the treatment of gingivitis patients in Himachal population

Journal of International Clinical Dental Research Organization, 2017
This study was conducted to analyze the changes in gingival health in patients treated with probiotic containing mouth rinse. Thirty volunteers between 20 and 35 years were randomly divided into two groups.
Vikas Jindal, Neha Mahajan, Amit Goel, Rupinder Kaur, Atin Mahajan, Puja Thakur Malhotra   +5 more
doaj   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Trafficking in Cure and Harm: Placebos, Nocebos and the Curative Imaginary

Disability Studies Quarterly, 2018
This article tracks the traffic of placebos, nocebos and the effects or meaning-responses that they solicit in order to contribute to wide-ranging critiques of the curative imaginary.
Suze G. Berkhout, Ada S. Jaarsma
doaj   +1 more source

Placebos without deception reduce self-report and neural measures of emotional distress

Nature Communications, 2020
There is controversy about whether placebos without deception cause real psychobiological benefits. Here, the authors show that the positive effects of placebos without deception are more than response bias by providing evidence they can reduce self ...
Darwin A. Guevarra, Jason S. Moser, Tor D. Wager, Ethan Kross   +3 more
doaj   +1 more source

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

From catastrophizing to catalyzing: does pain catastrophizing modulate the beneficial impact of open-label placebos for chronic low back pain? A secondary analysis

Frontiers in Psychology
Chronic back pain (CBP) is a global health problem with significant health and economic consequences. Traditional analgesics are often no better than placebo, highlighting the need for biopsychosocial approaches.
Elif Buse Caliskan, Elif Buse Caliskan, Katharina Schmidt, Andreas Hellmann, Tamás Spisák, Ulrike Bingel, Julian Kleine-Borgmann   +6 more
doaj   +1 more source